Melatonin
Circadin, Melatonin, Slenyto (melatonin) is a small molecule pharmaceutical. Melatonin was first approved as Circadin on 2007-06-29. It is used to treat jet lag syndrome and seasonal affective disorder in the USA. It has been approved in Europe to treat autistic disorder and sleep initiation and maintenance disorders. The pharmaceutical is active against melatonin receptor type 1B and melatonin receptor type 1A. In addition, it is known to target 5-hydroxytryptamine receptor 2B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 24 / 7 life extra strength pain reliever | OTC monograph final | 2023-07-19 |
| 24 / 7 life extra strength pain reliever pm | OTC monograph not final | 2023-07-19 |
| cardinal health | OTC monograph final | 2022-12-12 |
| cvs health earwax removal drops earwax removal aid | C200263 | 2024-06-24 |
| cvs health earwax removal kit | C200263 | 2024-06-17 |
| cvs health first aid outdoor prep-pack | OTC monograph not final | 2017-01-20 |
| cvs health nighttime sleep aid | OTC monograph final | 2017-10-18 |
| cvs health nighttime sleep-aid | C200263 | 2024-08-21 |
| dg health sleep aid | C200263 | 2024-07-17 |
| extra strength antacid tablets, 24/7 life extra strength antacid tablets, caseys 4good | OTC monograph final | 2023-08-16 |
Show 4 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
8289 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | â | F33.9 | 13 | 28 | 15 | 5 | 455 | 501 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 10 | 6 | 7 | 4 | 308 | 333 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 21 | 9 | 1 | 250 | 285 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 5 | 7 | 6 | 2 | 224 | 240 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 4 | 5 | 5 | 1 | 223 | 237 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 5 | 8 | 6 | 3 | 199 | 216 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 6 | 5 | 3 | 3 | 183 | 198 |
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | 4 | 5 | 2 | 182 | 197 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 4 | 16 | 9 | 4 | 167 | 191 |
| Covid-19 | D000086382 | â | â | 4 | 8 | 3 | 1 | 166 | 180 |
Show 232 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | â | C80 | 6 | 19 | 13 | â | 272 | 307 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 2 | 4 | â | 131 | 138 |
| Cardiovascular diseases | D002318 | HP_0001626 | â | 3 | 2 | 4 | â | 128 | 136 |
| Overweight | D050177 | â | E66.3 | 2 | 5 | 4 | â | 86 | 95 |
| Sleep | D012890 | GO_0030431 | â | 4 | 2 | 2 | â | 87 | 94 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 4 | 7 | â | 83 | 93 |
| Exercise | D015444 | EFO_0000483 | â | 2 | 2 | 1 | â | 89 | 92 |
| Health behavior | D015438 | â | â | 1 | 1 | 1 | â | 84 | 87 |
| Psychological distress | D000079225 | â | â | 2 | 2 | 1 | â | 75 | 79 |
| Obstructive lung diseases | D008173 | HP_0006536 | â | â | 2 | 1 | â | 75 | 78 |
Show 166 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pediatric obesity | D063766 | â | â | 1 | 2 | â | â | 65 | 67 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 2 | 3 | â | â | 44 | 48 |
| Caregiver burden | D000084802 | â | â | â | 1 | â | â | 36 | 37 |
| Healthy diet | D000072001 | â | â | 1 | 1 | â | â | 31 | 33 |
| Feeding and eating disorders | D001068 | â | F50 | 4 | 1 | â | â | 28 | 32 |
| Adolescent behavior | D000294 | â | â | 1 | 2 | â | â | 29 | 31 |
| Enuresis | D004775 | â | R32 | â | 1 | â | â | 30 | 31 |
| Body weight | D001835 | EFO_0004338 | â | 1 | 1 | â | â | 28 | 30 |
| Endometriosis | D004715 | EFO_0001065 | N80 | â | 1 | â | â | 21 | 22 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | â | 3 | â | â | 19 | 22 |
Show 149 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aging | D000375 | GO_0007568 | R41.81 | 1 | â | â | â | 61 | 62 |
| Mental health | D008603 | EFO_0003935 | â | 1 | â | â | â | 59 | 60 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | â | â | â | 45 | 46 |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | 1 | â | â | â | 35 | 36 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | â | â | â | 30 | 32 |
| Psychological burnout | D000077062 | â | â | 1 | â | â | â | 27 | 28 |
| Self efficacy | D020377 | â | â | 1 | â | â | â | 23 | 24 |
| Cerebral palsy | D002547 | â | G80 | 1 | â | â | â | 22 | 23 |
| Blood pressure | D001794 | EFO_0004325 | â | 1 | â | â | â | 20 | 21 |
| Respiratory tract infections | D012141 | â | J06.9 | 1 | â | â | â | 19 | 20 |
Show 94 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Suicide | D013405 | â | â | â | â | â | â | 62 | 62 |
| Feeding behavior | D005247 | â | â | â | â | â | â | 38 | 38 |
| Coronary disease | D003327 | â | â | â | â | â | â | 34 | 34 |
| Medication adherence | D055118 | EFO_0006344 | â | â | â | â | â | 34 | 34 |
| Colonic neoplasms | D003110 | â | C18 | â | â | â | â | 34 | 34 |
| Child development | D002657 | â | â | â | â | â | â | 29 | 29 |
| Suicide prevention | D000092864 | â | â | â | â | â | â | 26 | 26 |
| Pneumonia | D011014 | EFO_0003106 | â | â | â | â | â | 24 | 24 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | â | â | â | â | 24 | 24 |
| Patient participation | D010358 | â | â | â | â | â | â | 24 | 24 |
Show 1329 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Melatonin |
| INN | â |
| Description | Melatonin is a member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen atom is replaced by a 2-(5-methoxy-1H-indol-3-yl)ethyl group. It is a hormone secreted by the pineal gland in humans. It has a role as a hormone, an anticonvulsant, an immunological adjuvant, a radical scavenger, a central nervous system depressant, a human metabolite, a mouse metabolite and a geroprotector. It is a member of acetamides and a member of tryptamines. It is functionally related to a tryptamine. |
| Classification | Small molecule |
| Drug class | â |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc2[nH]cc(CCNC(C)=O)c2c1 |
Target
Alternate
NQO2
NQO2
Organism
Homo sapiens
Gene name
NQO2
Gene synonyms
NMOR2
NCBI Gene ID
Protein name
ribosyldihydronicotinamide dehydrogenase [quinone]
Protein synonyms
N-ribosyldihydronicotinamide:quinone reductase 2, NAD(P)H dehydrogenase, quinone 2, NAD(P)H menadione oxidoreductase-1, dioxin-inducible-2, NAD(P)H quinone dehydrogenase 2, NRH dehydrogenase [quinone] 2, NRH:quinone oxidoreductase 2, QR2, Quinone reductase 2, ribosyldihydronicotinamide dehydrogenase
Uniprot ID
Mouse ortholog
Nqo2 (18105)
ribosyldihydronicotinamide dehydrogenase [quinone] (Q9JI75)
Variants
No data
Financial
Revenue by drug
$
âŹ
ÂŁ
âŁ
No data
Estimated US medical usage
Melatonin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 99,277 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,853 adverse events reported
View more details
Š 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use